Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The ...

Management will participate in a fireside chat on Tuesday, March 3, 2026, at 11:50 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, ...

Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event ...

Wall Street finally started paying attention to Codexis (NASDAQ: CDXS) in 2017. But as investors are now being reminded, extra attention can bring extra scrutiny. While long-term investors have ...

Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ...

Despite nearly meeting its full-year 2019 product revenue guidance after just three quarters, the company didn't raise guidance. What does that mean? One sign of the business model's lumpiness is the ...

REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the ...

The small cap biotech company provided disappointing guidance for 2018. The disappointment came from full-year 2018 guidance. While total revenue is expected to rise 20% to 26% compared to 2017, the ...